bioAffinity Technologies Announces New Clinical Case Studies Demonstrating CyPath® Lung's Success in Early-Stage Cancer Detection and Reducing Unnecessary Procedures

Reuters
09/26
bioAffinity Technologies Announces New Clinical Case Studies Demonstrating CyPath® Lung's Success in Early-Stage Cancer Detection and Reducing Unnecessary Procedures

bioAffinity Technologies Inc. has announced the release of three new case studies demonstrating the clinical utility of its CyPath® Lung diagnostic test. The cases include detection of Stage 1A lung cancer following a positive CyPath® Lung result, as well as instances where the test helped avoid unnecessary invasive procedures in patients with indeterminate pulmonary nodules. According to the company, these case studies were provided by a Texas pulmonologist who has been using CyPath® Lung for over a year. The results from these cases have already been released by bioAffinity Technologies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250926999689) on September 26, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10